Moderna (NASDAQ:MRNA) was among the notable gainers on Wednesday after Oracle (NYSE:ORCL) Chairman Larry Ellison highlighted the AI's potential in the development of messenger RNA-based cancer ...

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to ...

Pharmaceutical company Moderna has been granted the funds to work on developing mRNA-based influenza vaccines, including for the strain causing the bird flu outbreak. Newsweek has contacted ...

↘️ MicroStrategy (MSTR): Cryptocurrencies pulled back after President Trump didn't mention crypto in his inauguration address. Shares in MicroStrategy, which also disclosed it had recently ...

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

Moderna will receive some $590 million from the U.S. government to develop messenger RNA vaccines for influenza strains, such as H5N1, that are seen as potential pandemic risks. Announced Friday as ...

Building on this legacy of innovation, LG did the unthinkable yet again with the announcement of the first-ever transparent OLED TV in the world in 2024. LG's see-through 77" TV with 4K UHD ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase III trial that will test out a vaccine against norovirus, a frequent ...

Moderna's recent stumbles make the company an acquisition target. Merck desperately needs Moderna's mRNA-based Personal Cancer Vaccines ("PCVs") to extend KEYTRUDA's patent protection beyond 2028 ...